12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

XAF5: Phase II started

Topokine began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily topical XAF5 gel in about 72 patients....

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >